Allergy Therapeutics (AGYTF) Lowered to Sell at Zacks Investment Research

Allergy Therapeutics (OTCMKTS:AGYTF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday, reports.

According to Zacks, “Allergy Therapeutics Plc is a specialty pharmaceutical company focused on allergy vaccination. The company’s product pipeline consists of PollinexTrees(R), Pollinex Grasses + Rye(R), Skin Prick Testing, Diagnostic Products and Service. Allergy Therapeutics Plc is based in Worthing, the United Kingdom. “

Shares of AGYTF remained flat at $$0.17 during midday trading on Thursday. The stock had a trading volume of 1,500 shares. Allergy Therapeutics has a 12 month low of $0.17 and a 12 month high of $0.19.

Allergy Therapeutics Company Profile

Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company's products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil.

Featured Article: What is the price-sales ratio?

Get a free copy of the Zacks research report on Allergy Therapeutics (AGYTF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with's FREE daily email newsletter.